Ten-year clinical outcomes in >1000 node-negative (N0) Estrogen Receptor (ER)+ breast cancer (BC) patients (Pts) where treatment decisions incorporated the Recurrence Score Results: a registry analysis using TAILORx categorization
Salomon M. Stemmer(Tel Aviv University), S. Shak(Einstein Medical Center Philadelphia), Noa Ben-Baruch(Kaplan Medical Center), A. Itay, Margarita Tokar, Beatrice Uziely(Hadassah Medical Center), Michelle Leviov(Haifa Medical Center), Ora Rosengarten(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), Georgeta Fried(Roche (Switzerland))
Cited by 2
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
|JNCI Journal of the National Cancer Institute|2013|523